BidaskClub lowered shares of Albireo Pharma (NASDAQ:ALBO) from a hold rating to a sell rating in a research note released on Thursday.
Other equities research analysts have also recently issued reports about the company. Needham & Company LLC initiated coverage on Albireo Pharma in a research note on Thursday, March 15th. They issued a buy rating and a $50.00 price target for the company. Wedbush reiterated a buy rating on shares of Albireo Pharma in a research note on Friday, January 19th. Zacks Investment Research upgraded Albireo Pharma from a hold rating to a buy rating and set a $33.00 price target for the company in a research note on Monday, January 8th. Finally, ValuEngine upgraded Albireo Pharma from a sell rating to a hold rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $57.60.
Shares of ALBO stock traded up $1.25 during trading on Thursday, hitting $34.03. The company had a trading volume of 68,476 shares, compared to its average volume of 70,730. The stock has a market cap of $393.20, a P/E ratio of -10.77 and a beta of 1.61. Albireo Pharma has a one year low of $15.31 and a one year high of $39.87.
Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Thursday, March 15th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.23. equities research analysts predict that Albireo Pharma will post 0.77 earnings per share for the current fiscal year.
In other Albireo Pharma news, major shareholder Phase4 Partners Ltd sold 100,000 shares of the company’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $34.44, for a total transaction of $3,444,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Life Sciences Maste Perceptive bought 275,000 shares of the business’s stock in a transaction on Thursday, January 25th. The shares were acquired at an average price of $33.00 per share, with a total value of $9,075,000.00. The disclosure for this purchase can be found here. 22.30% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALBO. Perceptive Advisors LLC lifted its stake in Albireo Pharma by 56.2% during the fourth quarter. Perceptive Advisors LLC now owns 1,320,000 shares of the biopharmaceutical company’s stock worth $33,792,000 after purchasing an additional 475,000 shares during the last quarter. Artal Group S.A. bought a new stake in Albireo Pharma during the fourth quarter worth $7,680,000. Sectoral Asset Management Inc lifted its stake in Albireo Pharma by 53.6% during the fourth quarter. Sectoral Asset Management Inc now owns 242,803 shares of the biopharmaceutical company’s stock worth $6,216,000 after purchasing an additional 84,776 shares during the last quarter. Millennium Management LLC lifted its stake in Albireo Pharma by 65.4% during the fourth quarter. Millennium Management LLC now owns 46,594 shares of the biopharmaceutical company’s stock worth $1,193,000 after purchasing an additional 18,425 shares during the last quarter. Finally, Ardsley Advisory Partners acquired a new position in shares of Albireo Pharma during the fourth quarter worth $289,000. Hedge funds and other institutional investors own 26.86% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “BidaskClub Lowers Albireo Pharma (ALBO) to Sell” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/20/bidaskclub-lowers-albireo-pharma-albo-to-sell.html.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis.
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.